Secretagogue Research Peptides

GHRPs activate the GHS-R1a receptor. Combined with GHRH analogues they are studied for a synergistic GH response. Selectivity differs: Ipamorelin has little effect on cortisol or prolactin, while GHRP-6 strongly stimulates appetite.

The secretagogue research peptides Ireland landscape: ghrelin receptor agonists

Secretagogues stimulate growth hormone release by a different route to GHRH analogues: rather than acting on the GHRH receptor, Ipamorelin, GHRP-2, GHRP-6 and Hexarelin activate the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. This receptor overlap with the hunger hormone ghrelin is central to why some of these sequences also carry notable appetite-related effects in published models.

For labs sourcing secretagogue research peptides Ireland catalogues typically group by selectivity, since GHRP-2, GHRP-6 and Hexarelin vary considerably in their secondary effects on cortisol, prolactin and appetite compared with the more selective Ipamorelin.

How secretagogues relate to one another and to GHRH compounds

Ipamorelin is the most studied for its selectivity — in the literature it shows a comparatively clean GH-release profile with minimal cortisol or prolactin co-release. GHRP-6 is notable for a pronounced appetite-stimulating effect linked to ghrelin receptor activation in the hypothalamus, while GHRP-2 sits between the two in terms of secondary hormone effects.

Hexarelin is a potent hexapeptide secretagogue also studied for cardiac tissue effects independent of GH release. Because secretagogues act on a distinct receptor to GHRH analogues such as Sermorelin, the two classes are frequently combined in synergy studies, exemplified by the CJC-1295/Ipamorelin blend.

Laboratory applications for ghrelin receptor agonist research

Common applications include GH synergy studies pairing a secretagogue with a GHRH analogue, appetite and feeding-behaviour models exploiting GHRP-6's ghrelin-linked activity, and receptor-selectivity comparisons profiling cortisol and prolactin co-release across the GHRP family.

In vitro pituitary cell assays are used to characterise each compound's potency at GHS-R1a, while in vivo rodent models extend this to systemic GH pulse amplitude, feeding behaviour and body-composition endpoints over longer observation periods.

Designing comparative secretagogue studies

Because selectivity differs sharply across this compound group, study design should specify which secondary endpoints — cortisol, prolactin, appetite — are being tracked alongside GH, and dosing schedules should be matched when comparing compounds head-to-head to avoid confounding differences in exposure duration.

Combination protocols with GHRH analogues require careful timing of administration relative to each compound's half-life, and researchers should record vehicle, reconstitution volume and storage temperature consistently across comparator groups.

Storage, reconstitution and quality control for GHRPs

Like other research peptides, secretagogues are supplied lyophilised and are most stable stored frozen or refrigerated prior to reconstitution. Once reconstituted, solutions should be kept refrigerated and used within the stated shelf life to avoid degradation that could affect receptor-binding assay results.

Kensington Labs Ireland issues a batch-specific certificate of analysis for every secretagogue, confirming HPLC purity and LC-MS verified identity, giving research teams working with secretagogue research peptides Ireland supply chains confidence in compound integrity before use.

Compound comparison

Research considerations

Selectivity and appetite effects vary widely, so pick the GHRP that fits the endpoints being measured.